GSK Shares Climb on $2.2 Billion Zantac Lawsuit Settlement
In This Article:
GSK topped the Stoxx Europe 600 index after the pharmaceutical company agreed to pay up to $2.2 billion to settle thousands of U.S. lawsuits over claims its discontinued heartburn medicine Zantac caused cancer.